



Scientist, Genomics
Job code 227DR

Description

Fate Therapeutics is currently seeking a talented and highly motivated genomic scientist with a strong background in Next Generation Sequencing (NGS) and single cell analysis methods to join a multidisciplinary team dedicated to the discovery of novel cellular therapeutics. The candidate will play a key role in NGS method development to perform genomic and transcriptomic characterization on Fate's engineered iPSC derived NK and T cell cancer immunotherapy products. The successful candidate must have knowledge of cutting-edge genomic engineering techniques as well as a strong expertise in genomic and transcriptomic characterization of genetically modified cells, preferably in a single-cell environment. The position will require innovative thinking, strong independent and collaborative research abilities, and excellent oral and written communication skills. This is a full-time, bench-level position reporting to the Associate Director, Genomics and is located at the Company's corporate headquarters in San Diego, California.

Responsibilities

- Play a key role in the method development for novel single-cell RNA, DNA, and proteogenomic NGS techniques, including the adaptation of recent cutting-edge single cell genomics technologies (10x Genomics, Perturb-seq, CITE-seq, CROP-seq, etc.).
- Perform single-cell genetic and transcriptional analysis to identify immune expression signatures and genomic perturbations of engineered cell therapy products.
- Work closely with the molecular biology and immunology groups to develop screening strategies to enable the detection of various genomic perturbations using barcoded NGS technologies.
- Execute robust bioinformatic data analysis workflows to support the analysis of single cell high-throughput sequencing data.
- Provide biological interpretation of analysis results and present analysis results in a clear and concise manner, to scientific audiences.

Qualifications

- Requires Ph.D. degree and 2+ years postdoctoral training in genetics, genomics, or bioinformatics or highly related discipline. Some industry experience is preferred.
- Robust experience in custom NGS library generation and relevant NGS method development.
- Experience in single-cell genomic and transcriptomic sequencing technologies and bioinformatic data analyses is needed.
- Experience in using NGS for the genomic characterization of genetically engineered cells including targeted deep sequencing, integration site analysis, copy number analysis, and off-target editing evaluation is preferred.
- Experience in pooled CRISPR library generation and screening, including downstream NGS library preparation is ideal.



- Some immunology understanding including T and NK cell biology and/or tumor biology is preferred.
- Excellent creativity, technical decision-making, and trouble shooting skills.
- Excellent communication and presentation skills is required.

Working Conditions and Physical Requirements

- Will require working with blood and cell lines of human and animal origin
- Will require working with hazardous materials
- 100% on-site work at corporate headquarters in San Diego, CA
- Occasional evening and weekend work will be required

The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time.

For consideration send cover letter and resume to: careers@fatetherapeutics.com and reference job code 227DL.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-specific antigens. The Company's immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.